ArticleJournal of the American Society of Nephrology : JASN2025
Mechanistic Differences between Torsemide and Furosemide.
Abstract read
In one paragraph
Article in Journal of the American Society of Nephrology : JASN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Randomized controlled trial on efficacy and safety of torsemide versus furosemide in patients with nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2026Trial
- Pharmacological options to relieve congestion in acute heart failure.Heart failure reviews · 2025Review
- Natriuretic response prediction equation for use with oral diuretics in heart failure.European heart journal · 2025Article
- Renal Dysfunction Across the Spectrum of Cardiogenic Shock: Mechanisms, Clinical Implications, and Therapeutic Strategies.Current heart failure reports · 2025Review
- Comparing Torsemide with Furosemide: Finally a Mechanistic Approach that Says, "Enough Already".Journal of the American Society of Nephrology : JASN · 2025Article
- Evolving Decongestion Strategies in the Management of Acute Heart Failure.Current treatment options in cardiovascular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Veena S RaoSection of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.ORCID 0000-0002-1623-3445
Zachary L CoxDepartment of Pharmacy Practice, Lipscomb University College of Pharmacy, Nashville, Tennessee.ORCID 0000-0002-4919-0146
Juan B Ivey-MirandaSection of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.ORCID 0000-0001-8800-7298
Daniel NevilleSection of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.
Natasha BalkcomSection of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.ORCID 0009-0008-0025-9182
Julieta Moreno-VillagomezSection of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.ORCID 0000-0001-6966-8795
Daniela Ramos-MastacheFacultad de Estudios Superiores Iztacala, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico.ORCID 0000-0002-7422-3480
Christopher MaulionSection of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.ORCID 0000-0002-2510-4266
Lavanya BellumkondaSection of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.
W H Wilson TangDepartment of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0002-8335-735
Sean P CollinsDepartment of Emergency Medicine, Vanderbilt University Medical Center and Veterans Affairs Tennessee Valley Healthcare System, Geriatric Research, Education and Clinical Center (GRECC), Nashville, Tennessee.ORCID 0000-0002-2305-9836
Eric J VelazquezSection of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.ORCID 0000-0003-2245-7477
Robert J MentzDuke University School of Medicine, Duke Clinical Research Institute, Durham, North Carolina.
F Perry WilsonSection of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.ORCID 0000-0002-2633-2412
Jeffrey M TurnerDivision of Nephrology, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut.ORCID 0000-0002-5733-949
Christopher S WilcoxDivision of Nephrology and Hypertension Center, Georgetown University, Washington, DC.
David H EllisonOregon Clinical and Translational Research Institute, Oregon Health and Science University, Portland, Oregon.ORCID 0000-0003-2915-265
James C FangDepartment of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, Utah.
Jeffrey M TestaniSection of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MTRANSFORM-HF CCCU01HL125511 · NHLBI · YALE UNIVERSITY · PI MENTZ, ROBERT JOHN, VELAZQUEZ, ERIC J · 2017 to 2021
$7.7MMechanism and Effects of Manipulating Chloride Homeostasis in Heart FailureR01HL139629 · NHLBI · YALE UNIVERSITY · PI JEFFREY M TESTANI · 2018 to 2026
$5.0MKidney biomarkers in treatment for acute decompensated heart failureR01DK130870 · NIDDK · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI ESTRELLA, MICHELLE M, TESTANI, JEFFREY M · 2021 to 2025
$3.7MTRANSFORM-HF DCCU01HL125478 · NHLBI · DUKE UNIVERSITY · PI CHAKRABORTY, HRISHIKESH · 2017 to 2021
$3.7MMechanisms of diuretic resistance in heart failureR01DK130997 · NIDDK · YALE UNIVERSITY · PI JEFFREY M TESTANI · 2022 to 2026
$3.7MCardio-Renal Effects of Torsemide vs. Furosemide: A TRANSFORM-HF Mechanistic Sub-StudyR01HL148354 · NHLBI · YALE UNIVERSITY · PI TESTANI, JEFFREY M · 2019 to 2022
$3.3MOptimizing Electronic Alerts for Acute Kidney InjuryR01DK113191 · NIDDK · YALE UNIVERSITY · PI WILSON, FRANCIS PERRY · 2018 to 2022
$3.1MNCATS NIH HHS UL1 TR001863NHLBI Division of Intramural Research National Institutes of Health (NIH) NIH R01HL139629, R01HL148354, R01DK130997, and R01DK130870NHLBI Division of Intramural Research R01DK113191 and P30DK079210NHLBI Division of Intramural Research U01-HL125478 and U01-HL125511NHLBI NIH HHS R01 HL139629NHLBI NIH HHS R01 HL148354NHLBI NIH HHS U01 HL125478NHLBI NIH HHS U01 HL125511NIDDK NIH HHS R01 DK113191NIDDK NIH HHS R01 DK130870NIDDK NIH HHS R01 DK130997
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.